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124Objectives: Neonates undergoing complex congenital heart surgery have a significant incidence of neurologic
problems. Erythropoietin has antiapoptotic, antiexcitatory, and anti-inflammatory properties to prevent neuronal
cell death in animal models, and improves neurodevelopmental outcomes in full-term neonates with hypoxic
ischemic encephalopathy. We designed a prospective phase I/II trial of erythropoietin neuroprotection in
neonatal cardiac surgery to assess safety and indicate efficacy.
Methods: Neonates undergoing surgery for D-transposition of the great vessels, hypoplastic left heart
syndrome, or aortic arch reconstruction were randomized to 3 perioperative doses of erythropoietin or placebo.
Neurodevelopmental testing using the Bayley Scales of Infant and Toddler Development III was performed at
age 12 months.
Results: Fifty-nine patients received the study drug. Safety profile, including magnetic resonance imaging brain
injury, clinical events, and death, was not different between groups. Three patients in each group died. Forty-two
patients (22 in the erythropoietin group and 20 in the placebo group; 79% of survivors) returned for 12-month
follow-up. In the group receiving erythropoietin, mean Cognitive Scale scores were 101.1  13.6, Language
Scale scores were 88.5  12.8, and Motor Scale scores were 89.9  12.3. In the group receiving placebo, Cog-
nitive Scale scores were 106.3 10.8 (P¼ .19), Language Scores were 92.4 12.4 (P¼ .33), and Motor Scale
scores were 92.6  14.1 (P ¼ .51).
Conclusions: Safety profile for erythropoietin administration was not different than placebo. Neurodevelop-
mental outcomes were not different between groups; however, this pilot study was not powered to definitively
address this outcome. Lessons learned suggest optimized study design features for a larger prospective trial to
definitively address the utility of erythropoietin for neuroprotection in this population. (J Thorac Cardiovasc
Surg 2013;146:124-31)Despite major advances in reducing mortality for neonatal
cardiac surgery, acute neurologic morbidity after cardiac
surgery (eg, seizures, coma, and movement disorders)
occurs in 1% to 25% of patients in recent reports.1,2
Long-term neurodevelopmental impairment is reported in
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The Journal of Thoracic and Cardiovascular Surgnewborns or young infants.3 Data from long-term follow-
up studies in preschool and school-aged children who
underwent surgery for congenital heart disease reveal
a spectrum of neurodevelopment-related problems that are
similar to those observed in low-birth-weight premature
infants, including problems with attention, language, mem-
ory, and sensorimotor functioning.3
Perioperative causes of neurologic injury include
cerebral hypoxia/ischemia due to cardiovascular patho-
physiology, surgical or cardiopulmonary bypass (CPB)
techniques, cerebral emboli, low cardiac output, and inter-
current events such as cardiac arrests.2,4,5 Pre- and
postoperative magnetic resonance imaging (MRI) studies
document a 36% to 73% incidence of new or worsening
white matter or other ischemic brain lesions after neonatal
cardiac surgery.6,7
Erythropoietin (EPO) is a 30.4 kilodalton glycoprotein
that has antiapoptotic, anti-inflammatory, and antiexcitatory
cell death effects, protecting the brain against a variety
of cerebral insults in animal and in vitro models.8,9
Human neonatal data show improved longer-termery c July 2013
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
EPO ¼ erythropoietin
FDA ¼ Food and Drug Administration
MRI ¼ magnetic resonance imaging
rSO2 ¼ regional cerebral oxygen saturation
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chemic encephalopathy.10 Because EPO is already used in
the neonatal population for prevention and treatment of ane-
mia and has a long record of safety, it is potentially a very
useful agent for neuroprotection in neonatal cardiac sur-
gery. The predictable period of known risk of potential
neurologic injury in neonatal cardiac surgery makes
pre-emptive intervention with EPO to protect the brain an
attractive concept. However, the effects of perioperative ad-
ministration of EPO, in the higher doses needed to provide
neuroprotection than those routinely used for anemia, are
not known. This phase I/II trial was designed to assess
safety and give preliminary indication of efficacy of EPO
treatment for neuroprotection in the perioperative period
for neonatal cardiac surgery, to help determine if larger
trials are warranted.
METHODS
This was a prospective, randomized, blinded, placebo-controlled trial of
EPO (Epogen; Amgen, Inc, Thousand Oaks, Calif) versus normal saline
control (FDA IND 100011, NCT00513240, www.clinicaltrials.gov). The
Baylor College of Medicine Institutional Review Board approved the pro-
tocol, and patients were enrolled after informed signed parental consent.
Inclusion criteria were neonates (aged<30 days) scheduled for cardiac
surgery with hypothermic CPB for>60 minutes. Three anatomic groups
were studied: (1) hypoplastic left heart syndrome or variant undergoing
Norwood Stage I palliation; (2) D-transposition of the great vessels under-
going arterial switch operation; and (3) interrupted aortic arch with ventric-
ular septal defect or other complete 2-ventricle anatomic repair, including
truncus arteriosus, tetralogy of Fallot, or total anomalous pulmonary
venous return. Randomization was performed by computer-generated ran-
dom number assignment to EPO or placebo, and patients were stratified
within each of these 3 anatomic groups.
Exclusion criteria were gestational age younger than 35 weeks at birth,
weight<2.0 kg, known recognizable dysmorphic syndrome, surgery not
requiring CPB, preoperative cardiac arrest, or inability to enroll the patient
>12 hours preoperatively. Also excluded were cases where aortic cross-
clamping was not used, CPB times were anticipated to be<60 minutes,
and a nadir temperature on bypass>30Cwas planned. In addition, patients
with contraindications to EPO administration were excluded. Exclusion
criteria included hypertension (sustained systolic blood pressure>100
mm Hg), polycythemia (hemoglobin>20 g/dL), thrombocytosis (platelet
count>600,000/dL), or evidence of hypercoagulability (international nor-
malized ratio<1.0), and patient or maternal history of major thrombosis.9
Patients underwent a detailed neurologic examination by a pediatric
neurologist, unless precluded by neuromuscular blockade or heavy seda-
tion. For a 12- to 24-hour period before the scheduled surgery, patients
had a near-infrared spectroscopy sensor (Somanetics 5100B, Inc, Troy,
Mich) placed on the right forehead, to measure regional cerebral oxygen
saturation (rSO2).The Journal of Thoracic and CaSurgical, anesthetic, and CPB techniques were standardized and have
been described in detail previously.7Bilateral rSO2wasmeasured intraoper-
atively andmaintained>90% during CPB. If rSO2 was<50% before or af-
ter bypass, attempts were made to increase oxygen delivery to the brain, or
decrease oxygen consumption, using a protocol described previously.7
BrainMRI under general endotracheal anesthesiawas obtained immedi-
ately before surgery.MRIwas performed on a 1.5 Tesla Intera scanner (Phi-
lips Medical Systems, Best, The Netherlands), including standard T1, T2,
diffusion weighted imaging, and susceptibility weighted imaging.7 Postop-
erative MRI was obtained when the patient was clinically stable, at 7 to 10
days postoperatively. All MRI scans were evaluated by pediatric neuroradi-
ologists unaware of diagnosis or surgery. Abnormalities were classified as
white matter injury, intraparenchymal infarction, or intraparenchymal or
intraventricular hemorrhage.7 Sinovenous thrombosis was diagnosed sepa-
rately, and confirmed by 2-dimensional time of flight magnetic resonance
venography with maximum intensity projection reconstructions. MRI
injury definitions and grading scale have been described in detail previ-
ously; all injuries were classified as mild, moderate, or severe.7
The initial protocol EPO doses were 1000 units/kg intravenously over
60 minutes (or placebo equivalent) in 3 doses: (1) 12 to 24 hours preopera-
tively, (2) immediately after CPB, and (3) 24 hours after dose 2. This dose
was chosen based on animal model data to provide sufficient brain tissue
EPO concentrations to afford neuroprotection.11 This schema was used in
the first 33 patients. The trial was placed on full clinical hold by the US
Food and Drug Administration (FDA) because of adverse events in an adult
EPO neuroprotection trial for stroke in patients aged 50 to 80 years not re-
lated to this neonatal cardiac surgery trial. After evaluation of safety data,
the FDAmandated a dosing regimen change in our trial. For the final 26 pa-
tients, EPOdosewas 500 units/kg intravenously preoperatively, and on post-
operative days 1 and 3.Aprotininwas administered to the first 21 patients for
antifibrinolysis. Aprotininmarketingwas suspended inDecember 2007, and
ε-aminocaproic acid was administered to the final 38 patients in the study.
Clinical data collection preoperatively, intraoperatively, and for the first
72 hours postoperatively included rSO2; hemodynamic and respiratory
data; details of CPB technique; and clinical events such as cardiac arrest,
extracorporeal membrane oxygenation cannulation, and clinical seizures.
The potential adverse effects of EPO include major thrombosis, intracra-
nial hemorrhage, hypertension, thrombocytosis, and polycythemia.9 These
events were defined as above under Exclusion Criteria, and were assessed
for each patient.
Chromosome analysis was performed by chromosomal microarray, or
fluorescence in situ hybridization analysis, when a genetic syndrome was
suspected. Anesthetic and sedative drug doses in the operating room, and
the first 72 postoperative hours in the intensive care unit were recorded.
Records were also reviewed for cardiac arrest, extracorporeal membrane
oxygenation cannulation, and deaths.
Neurodevelopmental testing was performed with the Bayley Scales of
Infant and Toddler Development, Third Edition11 (Bayley III) at age
12months. The Bayley III consists of 3 primary composite standard scores,
the Cognitive, Motor, and Language Composite scores, measured by per-
formance of specified tasks, scored against a normative population, and
scaled to have a mean score of 100 with standard deviation of 15. In addi-
tion, a parental questionnaire is administered, and Social-Emotional and
Adaptive Behavior Composite Scores are derived. These tests were admin-
istered by a single developmental psychologist unaware of diagnosis or sur-
gery performed, or if EPO or placebo had been administered. Maternal
intelligence was evaluated using the Weschler Abbreviated Scale of
Intelligence.12
A data and safety monitoring board, consisting of pediatric specialists in
neurology, cardiology/cardiac intensive care, congenital heart surgery,
hematology, neonatology, and cardiac anesthesiology, reviewed all safety
data and adverse events. Blinding of groups was maintained until the final
patient had undergone 12-month Bayley III assessment. The data and
safety monitoring board had access to unblinded data at all times.rdiovascular Surgery c Volume 146, Number 1 125
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DEPO Pharmacokinetic Data
Blood sampling for measurement of EPO pharmacokinetics was
performed in consenting patients with indwelling arterial or central venous
catheters. Sampling (0.5 mL) was performed immediately before the first
dose of EPO/placebo, and at 0, 1, 2, 4, 6, 12, and 24 hours after the
1-hour infusion. Immediately following collection, blood was centrifuged
at 760 3 g for 15 minutes at room temperature and plasma transferred to
plastic vials and frozen at 80C until analyzed. EPO concentrations
were determined using the commercially available Quantikine IVD
(R&D Systems, Inc, Minneapolis, Minn) EPO enzyme-linked immunosor-
bent assay kit. Because the assay does not discriminate between endoge-
nous and recombinant EPO, the baseline EPO level was subtracted from
the post-EPO administration concentrations.
Sample Size Calculation and Statistical Analysis
This was a pilot phase I/II trial, and the original plan was to enroll 80 pa-
tients, to allow for approximately 60 patients to undergo 12-month neurode-
velopment assessments, accounting for deaths andwithdrawal from the study.
This sample size would be expected to detect a difference of 7.5 points be-
tween groups on the Cognitive Scale score of the Bayley III, with a standard
deviation of 15, power of 80%, and a level of 0.05, using 2-sided t test for
comparison. Because the time period to enroll patients was significantly cur-
tailed by the full clinical hold imposed by the FDA, the enrollment goal was
reduced to 60, intended to yield 45 patients to evaluate at 12 months. This
sample size could only detect a difference of 9 points between groups.
Thus this study could only give a preliminary indication of efficacy of EPO
treatment on 12-month neurodevelopment-related outcomes.
A descriptive analysis of the pharmacokinetic data was planned due to
the study size, and elective participation in the pharmacokinetic analysis
component of the study, restricted to infants with indwelling catheters ca-
pable of blood sampling in the preoperative period. We anticipated that 10
to 15 patients would meet the inclusion criteria of parental consent,
indwelling catheter for blood samples, and ability to enroll the patient
>24 hours before scheduled surgery.
Analysis was performed on the intention-to-treat basis. The primary anal-
ysis was the safety profile for the EPO versus placebo groups, with sinove-
nous thrombosis, other major thromboses, hypertension, thrombocytosis,
and polycythemia as the primary outcomes. Also analyzed were MRI brain
injury pre- and postoperatively. Finally, neurodevelopment-related outcomes
were analyzed, including Cognitive, Language, and Motor Composite Stan-
dard Scores of the Bayley III scales. Data were analyzed using 2-sided t test,
Mann-Whitney signed rank test, Fisher exact test, analysis of variance, or c2
analysis as appropriate. Normally distributed data are reported as mean 
standard deviation; non-normally distributed data (Shapiro-Wilk test
P<.05) are reported as median (25th-75th percentile). Stata 12 (Stata Cor-
poration LLP, College Station Tex) was used for the analyses.
RESULTS
The study enrolled patients starting in September 2006,
and finished enrollment in February 2011. The enrollment
flow diagram is displayed in Figure 1. A total of 104 patients
met inclusion criteria. Sixty-two patients (60% of those el-
igible) were enrolled and randomized; 3 patients did not re-
ceive intended surgery, and did not have further data
collection, leaving 59 patients receiving study drug and
perioperative data collection. Patient clinical and perioper-
ative data are presented in Table 1. All patients survived the
immediate postoperative period.
The safety profile was similar between groups. Six pa-
tients had postoperative dural sinovenous thrombosis (3
from the EPO group, 3 from the placebo group); and 1 of126 The Journal of Thoracic and Cardiovascular Surgthese, an EPO group patient, had clinical seizures and
a new cerebral infarction in the area adjacent to the throm-
bosis on postoperative MRI. In the other 5 patients, there
were no clinical signs and sinovenous thrombosis was
only discovered on the postoperative MRI scan. Laboratory
workup for hypercoagulability was negative in all cases.
One patient with hypoplastic left heart syndrome who re-
ceived EPO experienced a cardiac arrest and required extra-
corporeal membrane oxygenation cannulation in the
immediate postoperative period. There were no other acute
adverse events, including no clinical seizures, coma, major
thromboses, hypertension, thrombocytosis, or polycythe-
mia in the immediate postoperative period until hospital
discharge. Clinical neurologic examination was performed
preoperatively by a pediatric neurologist in 44 of 59 pa-
tients, and before discharge in 45 of 59 patients. The only
abnormality noted was a slight symmetrical increase in
lower extremity deep tendon reflexes on the postoperative
examination in 1 patient with transposition of the great ar-
teries receiving placebo who had a moderate new white
matter injury, and a new germinal matrix hemorrhage on
postoperative MRI.
Six patients died before age 12 months (3 from the EPO
group, 3 from the placebo group). All patients who died had
hypoplastic left heart syndrome; 5 of 6 died in the interstage
period before a planned bidirectional cavopulmonary anas-
tomosis, and 1 after. Eleven patients declined 12-month
follow-up (7 from the EPO group, 4 from the placebo group;
P¼ .48), leaving 42 patients with 12-month Bayley III scale
scores (79% of survivors).
Brain MRI findings are presented in Table 2. Both preop-
erative baseline rate of injury, and postoperative outcomes
were not different in the EPO patients. There were no differ-
ences between groups in the classification of MRI injury
severity.
The neurodevelopment-related outcomes are presented
in Table 3. The outcomes of Bayley III Cognitive, Lan-
guage, and Motor Composite scaled scores were not differ-
ent between groups. We elected to analyze separately the
effect of cardiac diagnosis, the change of EPO dose status,
and change in aprotinin administration; results are pre-
sented in Tables 4 through 6. The only difference found in
these analyses was a higher Bayley III Cognitive Scale
score in placebo group patients who did not receive aproti-
nin. (Table 5) Maternal intelligence quotient for the infants
tested at 12 months was 104.5 14.6 in the EPO group, and
103.8 17.2 in the placebo group (P¼ .872). The anatomic
group of other complete 2-ventricle repairs (ventricular
septal defect with aortic arch repair, n ¼ 5; truncus repair,
n ¼ 2; and tetralogy of Fallot and total anomalous pulmo-
nary venous return, n ¼ 1 each) had the lowest overall
scores. Of note, 6 of 9 patients in this group had chromo-
some anomalies, all were microdeletions at the chromo-
some 22q11.2 region.ery c July 2013
FIGURE 1. Enrollment and data analysis flow diagram.
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placebo and 2 patients who received EPO 1000 units/kg.
Pharmacokinetic modeling was not performed because of
these small patient numbers; however, maximum EPO
plasma concentrations were 8415 and 5447 mIU/mL in
the 2 patients receiving EPO.
DISCUSSION
EPO treatment was not associated with an overall differ-
ence in complications, including major intracranial throm-
boses, hemorrhage, and other MRI findings; clinical
adverse outcomes; and death. Twelve-month Bayley III
scale scores were not different with EPO treatment; because
of the phase I/II pilot study design, this trial was not powered
to demonstrate a neurodevelopmental outcome difference.
Maximum EPO plasma levels in the 2 patients where they
were obtained demonstrated concentrations consistentThe Journal of Thoracic and Cawith neuroprotective levels in animal models for 1 patient,
and concentration below these levels in the other.13
ThisEPOneuroprotection study is the first published study
in the neonatal and infant cardiac surgery population to apply
a pharmacologic neuroprotection strategy, measure cerebral
physiology with near infrared spectroscopy, evaluate the
structural changes of the brainwithMRI, and assess the func-
tional outcomes with longer-term neurodevelopment-related
outcomes at age 12 months. The only previously published
randomized trial of pharmacologic neuroprotection in this
populationwas a study byClancy and colleagues14 of allopu-
rinol as an oxygen free radical scavenger versus placebo for
neonates undergoing deep hypothermic circulatory arrest for
Norwood stage I palliation or other complex repairs. There
was no effect of allopurinol treatment on the primary neuro-
logic outcome (ie, seizures, coma, or death). When cardiac
outcomes were included, the hypoplastic left heart syndromerdiovascular Surgery c Volume 146, Number 1 127
TABLE 1. Patient and operative characteristics
Parameter EPO group (n ¼ 32) Placebo group (n ¼ 27) P value
HLHS (n,%) 16 (50) 10 (37) .420
D-TGA (n,%) 9 (28) 12 (44) —
AAþVSD/other 2V (n,%) 7 (22) 5 (19) —
CPB time (min)* 191 (163-236) 194 (169-270) .382
Aortic crossclamp time (min)* 98 (84-129) 104 (89-148) .334
DHCA time (min)* 9 (8-14) (n ¼ 19) 11 (8-14) (n ¼ 10) .562
RCP time (min) 67.0  30.7 (n ¼ 23) 67.9  31.2 (n ¼ 14) .930
Lowest CPB temperature (C)* 17.9 (17.4-22.8) 18.1 (17.6-24.9) .266
OR fentanyl dose (mg/kg)* 182 (154-291) 198 (158-295) .755
OR midazolam dose (mg/kg) 0.96  0.46 1.21  0.49 .044y
Aprotinin use (n,%) 11 (34) 10 (37) .952
Isoflurane MAC-hours 1.78 (0.96-2.29) 1.58 (1.14-2.68) .879
Mean rSO2 (%) 69.6  7.1 71.2  7.4 .394
Data are mean  standard deviation if normally distributed. EPO, Erythropoietin; HLHS, hypoplastic left heart syndrome; D-TGA, dextrotransposition of the great arteries;
AAþVSD, hypoplastic aortic arch/ventricular septal defect; 2V, 2 ventricle; CPB, cardiopulmonary bypass; OR, operating room; DHCA, deep hypothermic circulatory arrest;
RCP, regional cerebral perfusion;MAC, minimum alveolar concentration; rSO2, regional cerebral oxygen saturation. *Data not normally distributed: median (25th-75th percen-
tiles). yP<.05.
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No imaging or longer-term outcomes were assessed.
EPO treatment shows promise to improve
neurodevelopment-related outcomes in other clinical set-
tings of neonatal brain injury. A prospective randomized
controlled trial in 153 full-term neonates diagnosed with
hypoxic ischemic encephalopathy demonstrated an im-
provement in neurodevelopment-related outcomes at age
18months afterEPO treatment every other day for 2weeks.10
Death or moderate/severe disability occurred in 44% infants
in the control group and 25% infants in the EPO group
(P ¼ .017). EPO improved outcomes only for infants with
moderate hypoxic ischemic encephalopathy (P ¼ .001)
and not those with severe injury (P ¼ .227) A second small
case control trial (n ¼ 45) in birth asphyxiated full term
TABLE 2. Brain magnetic resonance imaging (MRI) findings
Time period Parameter
Preoperative MRI injury Total with WMI, infarction, or hemorrhage
WMI
WMI severity: mild/moderate/severe (n)
Infarction (n,%)
Infarction severity: mild/moderate/severe (n
Hemorrhage (n,%)
Hemorrhage severity: mild/moderate/severe
DSVT
New postoperative MRI injury Total with new WMI, infarction, or hemorrh
WMI (n,%)
WMI severity: mild/moderate/severe (n)
Infarction (n,%)
Infarction severity: mild/moderate/severe (n
Hemorrhage (n,%)
Hemorrhage severity: mild/moderate/severe
DSVT (n,%)
DSVT severity: mild/moderate/severe (n)
Some patients had more than 1 type of injury, resulting in totals of WMI, infarction, and he
EPO, Erythropoietin; WMI, white matter injury; DSVT, dural sinovenous thrombosis.
128 The Journal of Thoracic and Cardiovascular Surgneonates found that EPO, 2500 units/kg subcutaneously
for 5 days, resulted in fewer neurologic and developmental
abnormalities at age 6 months than control patients (27%
vs 71%; P ¼ .03).15 In an EPO neuroprotection study in
extremely low-birth-weight neonates (<1000 g), 17 survi-
vors received either 500, 1000, or 2500 units/kg intravenous
EPO daily for the first 3 days of life. Compared with the 18
control subjects receiving no EPO, both cognitive
(P ¼ .044) and motor (P ¼ .026) scale scores were higher
with EPO, from 8 to 36 months corrected gestational age.16
There are recent data demonstrating apoptosis in response
to common anesthetic agents that bind g-aminobutyric acid
andN-methyl-D-aspartate receptors to produce their effects,
including halogenated anesthetic gases, benzodiazepines,
and ketamine. These drugs are frequently used in large dosesEPO group (n ¼ 32) Placebo group (n ¼ 27) P value
(n,%) 13 (41) 9 (33) .759
9 (28) 8 (30) .872
6/2/1 6/2/0 —
6 (19) 2 (7) .269
) 4/1/1 2/0/0 —
3 (9) 3 (11) .652
(n) 3/0/0 3/0/0 —
0 0 —
age 13 (41) 13 (48) .751
8 (25) 9 (33) .678
6/2/0 6/3/0 —
3 (9) 5 (19) .450
) 3/0/0 5/0/0 —
7 (22) 3 (11) .319
(n) 6/0/1 3/0/0 —
3 (9) 3 (11) .997
2/1/0 2/1/0 —
morrhage in each group being greater than the total number of brain-injured patients.
ery c July 2013
TABLE 3. Neurodevelopmental outcomes: 12 month Bayley Scales of Infant and Toddler Development III (Bayley III) Composite Scaled Scores
Variable Parameter EPO group (n ¼ 22) Placebo group (n ¼ 20) P value
Cardiac diagnosis HLHS (n,%) 11 (50) 6 (30) .298
D-TGA (n,%) 6 (27) 10 (50) —
AAþVSD/other 2V (n,%) 5 (23) 4 (20) —
Directly measured Bayley III
composite scores
Cognitive 101.1  13.6 106.3  10.8 .187
Language 88.5  12.8 92.4  12.4 .329
Motor 89.9  12.3 92.6  14.1 .506
Adaptive behavior: Bayley III
questionnaire scores
Social–emotional* 95.0 (92.5-105.0) 100.0 (96.3-108.8) .249
Behavioral 93.2  10.7 97.3  15.7 .342
Conceptual 98.7  13.6 99.2  13.1 .906
Social 97.2  11.4 100.7  15.6 .423
Practical 89.5  9.1 92.8  12.6 .352
Data are mean  standard deviation if normally distributed. EPO, Erythropoietin; HLHS, hypoplastic left heart syndrome; D-TGA, dextrotransposition of the great arteries;
AAþVSD, hypoplastic aortic arch/ventricular septal defect; 2V, 2 ventricle. *Data not normally distributed: median (25th-75th percentiles).
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agents is associated with worse neurodevelopment-related
outcomes in neonatal cardiac surgery, even after adjustment
for important covariates.17 There is now animal model data
demonstrating that EPO protects against anesthetic-induced
apoptosis and that anesthetics themselves suppress endoge-
nous EPO response to hypoxia.18 These potential benefits of
EPO treatment, as well as the demonstration of adequate
safety profiles of EPO in our trial, suggest that EPO in ade-
quate doses should be studied in a larger cohort of patients
undergoing neonatal cardiac surgery, with uniform dosing
and treatment protocols, to determine its value as a neuropro-
tectant in this setting.
Limitations of this study that affect the conclusions
reached with regard to the original intent of this phase I/II
trial can be summarized as follows. First is the change in
EPO dosing to levels that may not be neuroprotective. Sec-
ond is the reduction in the planned number of patients due to
the limited study period available. Third, timing of EPO
dosing with regard to the potential insult: a broader dosing
window could be more desirable, given the evidence for sig-
nificant incidence of preoperative MRI brain injury, and the
possibility that injury occurred later than postoperative day
3. Fourth, the lack of adequate numbers of patients for phar-
macokinetic data, and lack of data with regard to EPOTABLE 4. Bayley Scales of Infant and Toddler Development III (Bayley I
Parameter
12-Month Bayley III Cognitive HLHS* (n ¼ 11 EPO, 6 placebo)
12-Month Bayley III Language HLHS
12-Month Bayley III Motor HLHS*
12-Month Bayley III Cognitive D-TGA (n ¼ 7 EPO, 9 placebo)
12-Month Bayley III Language D-TGA*
12-Month Bayley III Motor D-TGA
12-Month Bayley III Cognitive AAþVSD/other 2V (n¼ 4 EPO, 5 placebo)
12-Month Bayley III Language AAþVSD/other 2V*
12 month Bayley III Motor AAþVSD/other 2V
Data are mean  standard deviation if normally distributed. EPO, Erythropoietin; HLHS
AAþVSD, hypoplastic aortic arch/ventricular septal defect; 2V, 2 ventricle. *Data not norm
The Journal of Thoracic and Capharmacokinetics with CPB. Finally, 6 of 42 patients had
chromosome 22q11.2 partial deletion, a condition with
known but variable associations with problems of
neurodevelopment.19
The limitations noted above, and the small size of this
EPO study preclude making any conclusions about EPO
neuroprotection in neonatal cardiac surgery populations.
However, as a phase I/II trial it is useful in that it demon-
strates no safety concerns of higher dose EPO administra-
tion, and gives important insight into optimized study
design features for a future EPO neuroprotection trial. Be-
sides studying a population large enough to determine
a meaningful difference in the primary neurodevelopment
outcome measure, future trials should include (1) more op-
timal EPO dosing, with the higher doses more likely to pro-
vide benefit; (2) more complete pharmacokinetic data,
necessary because of the unique features in this population
(ie, bypass); (3) more effective exclusion criteria and/or
screening to account for enrollment of subjects with chro-
mosome 22q11.2 microdeletions and other chromosomal
syndromes, at least assuring equivalent numbers in each
treatment group because these patients clearly affect the
outcomes19; (4) a plan for stratification based on rate of
preoperative MRI injury; (5) refinement of the EPO dosing
regimen given the issue of preoperative injury, withII) scores by anatomic/surgical group
EPO group Placebo group P value
100 (87.5-113.8) 100 (100-100) .990
90.3  15.1 90.0  9.7 .969
91.0 (91.0-97.0) 92.5 (79.0-110.0) .919
103.6  14.1 110.0  11.7 .335
91 (84.5-97.8) 94 (92.8-98.5) .284
92.4  12.0 97.3  12.3 .394
97.5  6.4 107.0  13.0 .228
78.5 (69.5-87.5) 91.0 (76.3-91.8) .190
85.0  12.7 86.8  11.7 .832
, hypoplastic left heart syndrome; D-TGA, dextrotransposition of the great arteries;
ally distributed: median (25th-75th percentiles).
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TABLE 5. Bayley Scales of Infant and Toddler Development III (Bayley III) scale scores by erythropoietin (EPO) dose: 1000 units/kg every day
(1000 QD ) for 3 doses versus 500 units/kg every other day (500 QOD) for 3 doses versus placebo
Parameter EPO 1000 QD (n ¼ 11) EPO 500 QOD (n ¼ 11) Placebo (n ¼ 20) P value
12-Month Bayley III Cognitive 101.4  16.9 100.9  10.2 106.3  10.7 .422
12-Month Bayley III Language 85.0  16.3 92.0  7.3 92.4  12.4 .268
12-Month Bayley III Motor 89.3  15.7 90.5  8.6 92.6  14.1 .787
Comparison by 1-way analysis of variance.
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Dconsideration to starting EPO dosing shortly after birth/di-
agnosis/randomization, and a longer period of treatment
(ie, up to 2 weeks); (6) an optimal primary outcome vari-
able: timing of neurodevelopmental testing at 12 months
versus later for greater predictive ability,20 issues with Bay-
ley III calibration (newer version of the test yields higher
Cognitive Scale score than the Mental Development Index
of the Bayley II),21 and utility of MRI (recent data demon-
strates an association with perioperative MRI brain injury
and lower neurodevelopment scores)22; and (7) stratifica-
tion and randomization according to anatomic diagnoses
with known worse neurodevelopment-related outcomes
(ie, hypoplastic left heart syndrome vs other diagnoses).23
Sample size considerations for an optimized EPO study
include choosing an appropriate primary outcome variable;
that is, the Cognitive Composite Score of the Bayley III at
age 18 to 24 months, powered to detect a difference of 5
points higher with EPO treatment. Assuming a power of
85% and a level of 0.05, 326 evaluable subjects would be
required, using 2-sided t test for comparison. This in turn
would likely mean that 435 patients would be required to
enroll in the study, accounting for a 25% death or study
dropout rate. This number would increase with stratification
by anatomic subgroup, or for interim analyses for safety
purposes. Such a study very likely requires multicenter par-
ticipation to enroll patients over a brief enough window of
time to ensure that outcomes do not change substantially
because of other unrelated improvements in therapy.TABLE 6. Bayley Scales of Infant and Toddler Development III
(Bayley III) scale scores by aprotinin administration status
Parameter EPO group Placebo group P value
12-Month Bayley III Cognitive
with aprotinin
(n ¼ 8 EPO, 8 placebo)
106.9  15.3 103.1  12.8 .604
12-Month Bayley III Language
with aprotinin
88.1  14.8 87.4  8.3 .902
12-Month Bayley III Motor
with aprotinin
94.3  12.3 87.3  15.3 .335
12-Month Bayley III
Cognitive no aprotinin
(n ¼ 14 EPO, 12 placebo)
97.9  11.9 108.3  9.1 .020*
12-Month Bayley III Language
no aprotinin
88.7  12.1 95.7  13.8 .184
12-Month Bayley III Motor
no aprotinin
87.4  12.1 96.2  12.4 .080
Data are mean  standard deviation. EPO, Erythropoietin. *P<.05.
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In this phase I/II trial, EPO treatment as a neuroprotectant
for complex neonatal cardiac surgery was not associated
with a different safety profile than placebo, including major
intracranial thromboses, hemorrhage, other MRI injuries,
and death. EPO treatment was not associated with an overall
difference in 12-month Bayley III scale scores in this small
group after analysis by the intent-to-treat basis; this study
was not powered to demonstrate an outcome difference.
Because of the limitations of changing EPO dose and apro-
tinin strategy during the study, a larger controlled trial would
be required to definitively address the status of EPO neuro-
protection for neonatal cardiac surgery. In addition, the sig-
nificant incidence of well-established preoperative brain
injury could potentially be addressed with earlier EPO treat-
ment; that is, immediately after birth if the patient had a pre-
natal diagnosis. Because we observed no differences in
adverse effects with EPO 1000 units/kg versus 500 units/
kg, and doses of at least 1000 units/kg are likely to be needed
for neuroprotection, we advocate a higher dose EPO strategy
for future trials in neonatal cardiac surgery. An optimized
study design, likely in a multicenter setting, will be required
to define the utility of EPO neuroprotection in neonatal car-
diac surgery populations. We advocate the pursuit of such
a study because of the many desirable properties of EPO
for neuroprotection and its demonstrated efficacy in other
setting of neonatal cerebral injury.
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